Skip to main content
. Author manuscript; available in PMC: 2023 Apr 26.
Published in final edited form as: Sci Transl Med. 2022 Aug 31;14(660):eabo6135. doi: 10.1126/scitranslmed.abo6135

Fig. 1. Population-scale immunopeptidomics and transcriptomics identify a shared pan-cancer epitope from a tumor-specific splice variant of COL6A3.

Fig. 1.

(A) Relative abundance of HLA-bound COL6A3-FLNV peptide isolated from tumor (red) and normal samples (blue). Each dot represents the median from five technical replicates of samples for which the peptide was detected and quantified. The number of donors with peptide detection, as well as the total number per group, is indicated in parentheses. (B) Absolute peptide copy numbers per cell were determined in a subset of samples. Each dot represents the mean across triplicates of each sample. (C) Heatmap of average log fold changes (FC) between tumor and average normal tissue samples for all protein-coding COL6A3 exons as determined by RNA sequencing. Missing log fold changes due to zero expression were indicated in gray. (D) Estimates for prevalence of patients positive for COL6A3-FLNV in selected tumor indications with exon 6 overexpression based on TCGA patient cohorts.